These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11157483)

  • 1. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis.
    Nogami K; Shima M; Giddings JC; Hosokawa K; Nagata M; Kamisue S; Suzuki H; Shibata M; Saenko EL; Tanaka I; Yoshioka A
    Blood; 2001 Feb; 97(3):669-77. PubMed ID: 11157483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation.
    Nogami K; Shima M; Nishiya K; Hosokawa K; Saenko EL; Sakurai Y; Shibata M; Suzuki H; Tanaka I; Yoshioka A
    Blood; 2002 Jun; 99(11):3993-8. PubMed ID: 12010799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
    Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
    Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
    Scandella D
    Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
    Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
    Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
    Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
    Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
    Gale AJ; Radtke KP; Cunningham MA; Chamberlain D; Pellequer JL; Griffin JH
    J Thromb Haemost; 2006 Jun; 4(6):1315-22. PubMed ID: 16706977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
    Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of factor VIII C2 domain in factor VIII binding to factor Xa.
    Nogami K; Shima M; Hosokawa K; Suzuki T; Koide T; Saenko EL; Scandella D; Shibata M; Kamisue S; Tanaka I; Yoshioka A
    J Biol Chem; 1999 Oct; 274(43):31000-7. PubMed ID: 10521497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
    Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
    Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization.
    Scandella D; Mattingly M; de Graaf S; Fulcher CA
    Blood; 1989 Oct; 74(5):1618-26. PubMed ID: 2477082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.
    Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D
    Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia.
    Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes.
    Gilles JG; Lavend'homme R; Peerlinck K; Jacquemin MG; Hoylaerts M; Jorieux S; Mazurier C; Vermylen J; Saint-Remy JM
    Thromb Haemost; 1999 Jul; 82(1):40-5. PubMed ID: 10456452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of Factor VIII A2 Domain Residues 400-409 to a Factor X-Interactive Site in the Factor Xase Complex.
    Takeyama M; Nogami K; Sasai K; Furukawa S; Shima M
    Thromb Haemost; 2018 May; 118(5):830-841. PubMed ID: 29614522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of factor VIII inhibitors.
    Shima M
    Int J Hematol; 2006 Feb; 83(2):109-18. PubMed ID: 16513528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
    Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
    Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.